Valion Bio VBIO
NASDAQ VBIO
$0.54 +0.02 (+3.85%)
At close: Nov 13, 2026 · 4:00 PM EST

Valion Bio (VBIO) Convertible Debt (2025 - 2026)

Updated

Valion Bio's Convertible Debt was $7.39 million in Q2 2026.

Analysis

Valion Bio (VBIO) Convertible Debt (2025 - 2026) Analysis & Trends

At the end of FY2025, Convertible Debt at Valion Bio came in at $6.45 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn
10 Valion Bio 73,008.00 -25.39 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 7.39 Mn
Mar 31, 2026 6.90 Mn
Dec 31, 2025 6.45 Mn
API Access

Valion Bio Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=VBIO&period=max&api_key=YOUR_API_KEY